BI-836858

N/A

Report date: 2026/03/23 20:03:44

Base Information

Drug NameBI-836858
Drug Alias NameAntiCD33 mAbFc-engineered IgG1 mAb to CD33BI-836858
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionMyeloid cell surface antigen CD33 inhibitors
TargetsMyeloid cell surface antigen CD33
Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItalyGermany +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesC.H. Boehringer Sohn Ag & Co. Kg
China Registration ClassN/A

Develop Information

Active CompaniesC.H. Boehringer Sohn Ag & Co. Kg
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsMyelodysplastic Syndromes

Other Information

ATC CodeN/A
Related LinksN/A